Logo

Sofinnova Raises $799m For European Biotech

1 min read
Sofinnova Raises $799m For European Biotech image

Europe's biotechnology sector has attracted a substantial new pool of growth capital, with investment firm Sofinnova Partners closing a $799 million fund aimed at companies approaching commercialisation. Announced on 16 November, the fundraising offers a measure of investor confidence in medical innovation despite a difficult financing environment.

The fund, Crossover II, exceeded its original target and is the largest Sofinnova has raised. It plans to support around 15 biotechnology and medical technology businesses, primarily in Europe, with selective investments in the United States and other markets. These are companies moving beyond early research towards clinical development, product launches or possible stock market listings.

Sofinnova has already invested through the fund in Hemab Therapeutics, which develops treatments for rare diseases, CellCentric, a developer of multiple myeloma therapies, and Neurent Medical, which makes devices for chronic rhinitis. Its approach includes working with management teams on clinical trials, leadership and potential listings, rather than providing capital alone.

The strategy addresses a persistent weakness in European life sciences. Scientific research and promising start-ups are plentiful, but securing sufficient money to complete costly trials and build international businesses can prove harder. Sofinnova partner Kinam Hong argues that the region faces a growth-financing problem, not a shortage of innovation.

For investment managers, the successful fundraising illustrates demand for specialist firms able to assess clinical risk and support companies over several years. Later-stage healthcare investments may offer substantial returns, but uncertain trial outcomes, regulation and lengthy development schedules can make valuations difficult. Governments also face competing pressure to fund innovative treatments while controlling healthcare budgets.

Sofinnova's first crossover fund backed Amolyt Pharma, later acquired by AstraZeneca, and French drug developer Abivax. The new vehicle does not guarantee similar outcomes. Its significance lies in providing companies with a route to larger funding rounds without requiring an immediate sale, potentially helping more European discoveries develop into enduring businesses.

Share this article: